Evidence map›Paper›PMID 40092832›Full record

ArticleACS omega2025

SI/II Pocket of Ras: An Opportunity for a Once "Undruggable" Target.

Tanos C C França, Michael Maddalena, Imène Kouidmi, Yann Ayotte, Salim T Islam, Steven R LaPlante

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tanos C C FrançaINRS Centre Armand Frappier Santé Biotechnologie, 531 des Prairies Boulevard, Laval, Quebec H7 V 1B7, Canada.ORCID https://orcid.org/0000-0002-6048-8103
Michael MaddalenaInstitut National de la Recherche Scientifique (INRS), Centre Armand-Frappier Sante Biotechnologie, Universite du Quebec, Institut Pasteur International Network, Laval, QC, H7V 1B7, Canada.
Imène KouidmiInstitut National de la Recherche Scientifique (INRS), Centre Armand-Frappier Sante Biotechnologie, Universite du Quebec, Institut Pasteur International Network, Laval, QC, H7V 1B7, Canada.
Yann AyotteNMX Research and Solutions Inc., Laval, Québec H7 V 5B7, Canada.
Salim T IslamInstitut National de la Recherche Scientifique (INRS), Centre Armand-Frappier Sante Biotechnologie, Universite du Quebec, Institut Pasteur International Network, Laval, QC, H7V 1B7, Canada.ORCID https://orcid.org/0000-0001-6853-8446
Steven R LaPlanteNMX Research and Solutions Inc., Laval, Québec H7 V 5B7, Canada.ORCID https://orcid.org/0000-0003-2835-5789

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations on the Ras-family of small GTPases are among the most common molecular oncogenic drivers, with the HRas isoform being primarily associated with head-and-neck and genito-urinary cancers. Although once considered "undruggable," recent efforts have identified a structurally conserved surface pocket in the Ras family, designated the SI/II pocket, situated near the binding site of the guanidine exchange factor (GEF) SOS1. The SI/II pocket may represent a potential target site for a pan-Ras drug. A crystal structure representing the native state of GDP-bound HRas

Identifiers

PMID40092832
PMCPMC11904710

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.